Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.37 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.37 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.37 |
| ▸ | TACR2 | P21452 | 3/20 | 0.35 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | FGF1 | P05230 | 2/20 | 0.34 |
| ▸ | FGF2 | P09038 | 2/20 | 0.34 |
| ▸ | VEGFA | P15692 | 2/20 | 0.34 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14850038 | 1.00 | PDPK1 (0.39) | PDPK1MTORSSTR1SSTR2SSTR4 | |
| SCHEMBL26273822 | 0.95 | PDPK1 (0.40) | PDPK1MTORSSTR1SSTR2SSTR4 | |
| SCHEMBL17773520 | 0.91 | PDPK1 (0.39) | PDPK1MTORSSTR1SSTR2SSTR4 | |
| SCHEMBL18573702 | 0.89 | PDPK1 (0.43) | PDPK1MTORSSTR1SSTR2SSTR4 | |
| SCHEMBL10148767 | 0.88 | PDPK1 (0.42) | PDPK1MTORSSTR1SSTR2SSTR4 | |
| SCHEMBL10117423 | 0.87 | PDPK1 (0.36) | PDPK1MTORSSTR1SSTR2SSTR4 | |
| SCHEMBL17521890 | 0.87 | ALDH1A1 (0.40) | PDPK1MTORTACR2TSHR | |
| SCHEMBL14667229 | 0.87 | SSTR1 (0.44) | PDPK1MTORSSTR1SSTR2SSTR4 | |
| SCHEMBL16837354 | 0.85 | PDPK1 (0.40) | PDPK1MTORSSTR1SSTR2SSTR4 | |
| SCHEMBL21657116 | 0.85 | HTR1A (0.45) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9005906-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140315979-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-8796437-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8586550-B2 | Thiazole derivatives as SGLT2 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2013-11-19 | — | — | US | disclosed |
| US-8541380-B2 | C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same | GREEN CROSS CORPORATION (KR) | 2013-09-24 | — | — | US | disclosed |
| US-20130211064-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8440803-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20130090298-A1 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same | GREEN CROSS CORPORATION (KR) | 2013-04-11 | — | — | US | disclosed |
| US-20120101051-A1 | NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-04-26 | — | — | US | disclosed |
| US-20120071645-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120021515-A1 | OLIGOMERIC COMPOUNDS AND METHODS | ISIS PHARMACEUTICALS, INC. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090298-A1 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same | SLC5A2, SLC5A1, SLC10A2 | PDPK1 833/4885MTOR 515/4885SSTR1 2285/4885 |
| US-20120101051-A1 | NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | SLC5A2, SLC5A1, SLC2A2 | PDPK1 1422/4885MTOR 1149/4885SSTR1 2149/4885 |
| US-20120021515-A1 | OLIGOMERIC COMPOUNDS AND METHODS | HNRNPH1, RNASEH1, SNRPE | PDPK1 4389/4885MTOR 4475/4885SSTR1 4158/4885 |
| US-20120071645-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | HNRNPM, POLM, RNMT | PDPK1 3349/4885MTOR 2659/4885SSTR1 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.